Decoding TNF receptor superfamily control of CD4+Foxp3+ Regulatory T cell-mediated tolerance: implications for the treatment of graft-versus-host disease
Targeting specific immune receptors could expand beneficial regulatory T cells during cancer treatment while preserving anti-tumor activity.
This comprehensive review synthesizes TNFRSF member roles in Treg biology for GvHD management, identifying TNFR2 and DR3 agonism as the most promising selective Treg-expansion strategies that preserve graft-versus-leukemia activity, while cautioning against OX40/GITR approaches due to context-dependent paradoxical effects. The review provides a practical roadmap for optimizing Treg manufacturing and tolerance induction in hematologic malignancy transplant settings.
What the study was
- Study design
- Narrative review; systematic analysis of TNFRSF members (TNFR2, OX40, CD40, Fas, CD27, 4-1BB, GITR, DR3) in Treg biology; translational roadmap for GvHD therapy
- Population
- Patients with hematologic malignancies and GvHD undergoing allogeneic transplantation (review scope)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cell Communication and Signaling
Why it surfaced
Comprehensive TNFRSF/Treg translational review with practical roadmap for GvHD therapy. Score limited by review design (no new data) and classification_confidence medium (review without systematic search criteria reported).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.